Diabetic retinopathy is a severe, sight-damaging complication of diabetes. Early diagnosis minimises the risk of fatal complications and sight loss. For this reason, everyone with diabetes should undergo an eye examination every year. More than 40% of patients do not undergo regular examination, however. Aireen® allows for fast, precise, pain-free and accessible eye screening for patients with diabetes.
In just 60 seconds, Aireen® assesses a retina image with high precision.
- Secure - High sensitivity and very low on false positives
- Comfortable - Result in less than 60 seconds
- Prooven - through clinical trials
Since May 2023 Aireen® diabetic retinopathy screening has been certified as class IIb EU-MDR medical device.